上皮性卵巢癌中血管内皮生长因子表达的临床意义  

Clinical significance of expression of vascular endothelial growth factor in epithelial ovarian cancer

作　　者：谢聪[1] 尹如铁[1] 游小林[1] 李克敏[1] 

机构地区：[1]四川大学华西第二医院妇产科、出生缺陷与相关妇儿疾病教育部重点实验室,成都610041

出　　处：《中华妇幼临床医学杂志（电子版）》2017年第1期34-38,共5页Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)

基　　金：中国癌症基金会基金资助项目(2014025)~~

摘　　要：目的探讨上皮性卵巢癌(EOC)中血管内皮生长因子(VEGF)表达的临床意义。方法选择2003年10月至2008年7月,在四川大学华西第二医院接受初次手术治疗,并获得满意肿瘤细胞减灭术治疗效果,术后肿瘤组织病理学检查确诊为EOC,有完整的临床组织病理学资料,组织标本在本院病理科有存档的65例EOC患者为研究对象。采用免疫组织化学法检测EOC患者的石蜡组织标本中VEGF表达情况。根据石蜡组织标本VEGF表达呈阳性或阴性,将65例EOC患者分为VEGF+组与VEGF-组。统计学分析VEGF+组与VEGF-组患者的年龄、国际妇产科联盟(FIGO)临床分期、肿瘤组织分化程度、淋巴结转移和(或)脉管浸润与否、肿瘤组织病理学类型、铂类药物耐药或敏感情况。结果1本研究65例EOC患者中,VEGF+为35例,纳入VEGF+组;VEGF-为30例,纳入VEGF-组。2VEGF+组与VEGF-组患者年龄,以及有、无淋巴结转移和(或)脉管浸润,肿瘤组织病理学类型,铂类药物耐药或敏感构成比分别比较,差异均无统计学意义(P>0.05)。VEGF+组患者FIGO临床期为晚期(Ⅲ~Ⅳ期)所占比例,显著高于VEGF-组,并且差异有统计学意义(χ~2=6.49,P=0.02)。VEGF+组患者肿瘤组织标本的中、低分化程度所占比例,显著高于VEGF-组,差异亦有统计学意义(χ~2=4.97,P=0.04)。结论对于FIGOⅢ~Ⅳ期,中、低分化EOC患者,术后化疗联合VEGF抑制剂治疗,可能获益更大。不能通过检测患者癌组织VEGF表达情况,预测患者是否会对含铂类药物的化疗产生耐药。Objective To analyze the clinical significance of expression of vascular endothelial growth factor （VEGF） in epithelial ovarian cancer （EOC）. Methods A total of 65 cases of EOC patients who underwent surgery for the first time and postoperative chemotherapy in West China Second University Hospital from October 2003 to July 2008, and had complete clinical and pathological data were included as research subjects. VEGF expressions of archived specimens of the 65 patients were detected by immunohistochemical method. According to the expression of VEGF were positive or negative, those 65 patients were divided into VEGF＋ group and VEGF group, respectively. The age, International Federation of Gynecology and Obstetrics （FIGO） stage, degree of differentiation, with or without lymph node metastasis and （or） vascular invasion, pathological type, platinum-resistant or platinum-sensitive between two groups were analyzed by statistical methods. Results ① Among those 65 cases patients with EOC, 35 cases were VEGF＋ and they were included into VEGF＋ group. 30 cases were VEGF- and they were included into VEGF- group. ②There wereno statistical differences between two groups in age, constituent ratios of with or without lymph node metastasis and （or） vascular invasion, pathological type, platinum-resistant or platinum-sensitive （P〈0.05）. The proportion of advanced FIGO stage （Ⅲ-Ⅳ stage） patients of VEGF＋ group was higher than that of VEGF- group, and the difference was statistically significant （χ2= 6. 49, P= 0.02）. The proportion of patients with middle to low differentiation of VEGF＋ group was higher than that of VEGF- group, and the difference was statistically significant （ 2 = 4. 97, P = 0. 04）. Conclusions Postoperative chemotherapy combined with VEGF inhibitor may improve curative effect in patients with EOC in FIGOⅢ-Ⅳstage, middle to low differentiation. We can not predict platinum- based chemotherapy drugs resistance by detecting VEGF expression.

关 键 词：血管内皮生长因子 卵巢上皮性癌 铂类化疗药物 抗药性 肿瘤 

分 类 号：R737.31[医药卫生—肿瘤]